4.8 Review

Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma

期刊

FRONTIERS IN IMMUNOLOGY
卷 9, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.01017

关键词

optineurin; neuroinflammation; autophagy; vesicular trafficking; amyotrophic lateral sclerosis; glaucoma

资金

  1. National Health and Medical Research Council of Australia (NHMRC) [10305133, 1086887]
  2. MND Research Institute of Australia
  3. NHMRC Dementia Team Research grant [1095215]
  4. Macquarie University PhD scholarship
  5. National Health and Medical Research Council of Australia [1086887] Funding Source: NHMRC

向作者/读者索取更多资源

Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and glaucoma, affect millions of people worldwide. ALS is caused by the loss of motor neurons in the spinal cord, brainstem, and brain, and genetic mutations are responsible for 10% of all ALS cases. Glaucoma is characterized by the loss of retinal ganglion cells and is the most common cause of irreversible blindness. Interestingly, mutations in OPTN, encoding optineurin, are associated with both ALS and glaucoma. Optineurin is a highly abundant protein involved in a wide range of cellular processes, including the inflammatory response, autophagy, Golgi maintenance, and vesicular transport. In this review, we summarize the role of optineurin in cellular mechanisms implicated in neurodegenerative disorders, including neuroinflammation, autophagy, and vesicular trafficking, focusing in particular on the consequences of expression of mutations associated with ALS and glaucoma. This review, therefore showcases the impact of optineurin dysfunction in ALS and glaucoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据